

Information to Help Complete the Universal Enrollment and Prescription Form

The Universal Enrollment and Prescription Form acts as both a prescription for SYNAGIS® (palivizumab) and consent to enroll in SYNAGIS CONNECT[®], Sobi's patient support program. This can be completed as a paper form and faxed to SYNAGIS CONNECT[®] or to the preferred specialty pharmacy, or it can be completed electronically through the CoverMyMeds[®] portal.

If SYNAGIS CONNECT® has previously received an Authorization for the Transition of Care and Parent/Caregiver Consent form for your patient from the neonatal intensive care unit, your office will be provided a partially completed version of this form via fax or CoverMyMeds[®] if your office uses the CoverMyMeds[®] portal.

Make sure all fields are complete before sending the form back to SYNAGIS CONNECT® or to the preferred specialty pharmacy.

	SYNAGIS W CONNECT	Universal Enrollment and Prescription Form	SYNAGIS [®] PALIVIZUMAB		Healthcare professionals can select Buy-and-Bill or Preferred Specialty Pharmacy.
	• Enroll or	line at www.CoverMyMeds.com. • Fax to SYNAGIS CON	NECT* at 1 800 201 4938		
	O Buy-and-Bill Benefit O Preferred Spe				Patient weight will be documented toward
z	PATIENT INFORMATION OPlease ind				the bottom of this page for prescribed
2	Last Name:	First Name:	Middle Initial:		dosage under Clinical Information.
Ā	Date of Birth*:///	Sex: O Male O Female (*Patient weight inf	ormation is collected in the prescription section.	+	uosage under chinical information.
Ş.	PARENT/CAREGIVER INFORMATION		NAME OF A DESCRIPTION OF A		
ō	Last Name: Street:	First Name: Unit: City:	Middle Initial: State: ZIP Code:		Parents/caregivers can choose to fill in
ž	Home Phone #:	Mobile Phone #:			
~	Email:		tact Method: 🔿 Phone 🛛 Text 🔿 Email		the red circles to consent to
ž	Best Time to Call: O Morning O After	noon O Evening Preferred Language:			• Enroll in the Copay Program, if eligible
ש	Enroll me in the SYNAGIS Copay Progra	m. I authorize SYNAGIS CONNECT® to send text message	is authorize SYNAGIS CONNECT* to leave a detailed message, including the name of my		
×.	Eligibility requirements apply.	when appropriate and hereby agree to receive this Type communication. Standard data and message rates may			 Receive text messages from
រឹ	INSURANCE INFORMATION Please pro	ovide a copy of all insurance cards (front and back).	O No Insurance		SYNAGIS CONNECT®
È	Policyholder Full Name:		yholder Date of Birth:///		• Receive detailed voice messages from
PATIENT/CAREGIVER INFORMATION	Primary Medical Insurance:	Carrier He	10.44		
F	Insurance Phone #: Secondary Medical Insurance:	Group #:	ID #:		SYNAGIS CONNECT®
•	Insurance Phone #:	Group #:	ID #:		If any option is chosen, both signatures
	Prescription Insurance:	RxGrou	RxPCN:		for consent are required on page 2.
		FOR HEALT	LY 🔻		for consent are required on page 2.
	PRESCRIBER INFORMATION				
	Last Name: Street:	First Name: Office	/Institution Name: State:ZIP Code:		A second signature from the
LS I	NPI #:	DEA #: DEA #:			prescriber is required to consent
IAI	Medicaid Provider ID #:				
DET	Office Contact Name:	Phone #: Email:			to the Prescriber Authorization.
RIPTION	that I provide on this form will be used by the program for purposes of verifying my parent/caregiver by telephone or mail for these purposes. I authorize SYNAGIS CON receive any benefit from Sobi for doing so. I will not seek reimbursement from any t	person named on this form is my patient; that the information provided, to the best of my knowledge, is a picticable stars and federal laws to relate the individually identifiable health information included on this interference and epilositic constraints of the depending of my patient presentation models (ECT to Internet the above prescription to the appropriate prescription models) planmary for my patient. Lundersta ministry pare or generation test my barry posterior provide free of the para SPMAGC SUNIECT, door, For prescribers in states with official prescription from requirements, please submit an actual prescrip-	complete and accordance and that therapy with STMCGS is modeling increasingly, costing that that an elaboration to its both and STMCGR COMPECT particular parging and induced that the information era and introducing STMCGS COMPECT pargon particular particular to the information of the information of the international structure of the structure and the information of the information and international structure and the information of the information of the information and the information of the structure and the information of the information of the information and the information of the structure and the information of the information of the information and the information of the information and the information of the information and the information of the		The Clinical Information section includes details pertaining to diagnosis and a
ESCR	SIGN HERE Prescriber Signature		Date		reminder to attach clinical documentation.
We want	CLINICAL INFORMATION Attach any requi	red clinical notes.			l'entitidei to acaden entitedi docamentationi
	O Prematurity: weeks'/days' GA (eg, 32.3)	OBronchopulmonary dysplasia/chronic lung disease	O Hemodynamically significant congenital heart disease		
AN	ICD-10:	OAge <12 months OAge 12 months to <24 months	OAge <12 months OAge 12 months to <24 months ICD-10:		• The Prescription section covers either
	Birth Weight: kg	Supplemental oxygen (dates): Chronic corticosteroids (drugs/dates):	Other conditions:		strength of SYNAGIS at QS to achieve
NO	Current Weight:kg	Diuretic therapy (drug/dates):	Discription:		the 15 mg/kg dose
BER INFORMATI	Date of Weight:///	Bronchodilators (drugs/dates): ICD-10:	Diagnosis: ICD-10:		
Ş	NICU/Hospital dose administered: O No O Yes Current medications:	Date(s): Needs by date: Known allerzies:	Expected date of first/next injection:		• Prescription for epinephrine is optional
ö	Deliver to: Office/Clinic OPatient's Home O				• The prescriber can choose to fill in the
ž		jection Administration ONo OYes Preferred Home Hea	Ith Agency		red circle to include ancillary supplies
~	MEDICATION STRENG		QUANTITY & REFILLS		
Ш	SYNAGIS* (palivizumab) 50 mg and/or 100 OPTIONAL: Epinephrine 1:1000 an		Quantity: QS to achieve 15 mg/kg dose Refills: Quantity: Refills:		as needed for administration, such as
R R	O Ancillary supplies	Stamp Signature Not Allowed	· · · · · · · · · · · · · · · · · · ·		syringes, with the prescription
ES	SIGN HERE Prescriber Signature	Sump Signature Not Allowed	Date		• The prescriber can determine dosage
K	OR	Dispense as Written			strength based on the patient's weight
	Prescriber Signature	Substitution Permitted	Date		su engui based on the patient's Weight
		PARENT/CAREGIVER CONSENT CONTINUED ON N	IEXT PAGE	//	
		Not Required for Submission		7	Prescriber signature required for
		101.2			either Dispense as Written or
L				- L	
					Substitution Permitted. Stamp
			aregiver consent on page 2.		signatures are not allowed.
	1011	the second se	na ana ka na sa kana manaka ku ana k		

If the parent/caregiver cannot be reached, this page can be sent separately and SYNAGIS CONNECT[®] will reach out to the parent/caregiver to obtain consent.



Information to Help Complete the Universal Enrollment and Prescription Form

The Authorization to Share Health Information and Consent for Enrollment in SYNAGIS CONNECT® must each be signed in order for SYNAGIS CONNECT® to provide services.

If necessary, this page can be omitted from initial submission if attempts to connect with the patient's parent/caregiver fail. If parent/caregiver is not available to sign, SYNAGIS CONNECT® will reach out to obtain parent/caregiver consent.



Patient name and date of birth must be

Parents/caregivers can choose to fill in the red circles to consent to receive marketing calls and text messages from SYNAGIS CONNECT[®].



Information to Help Complete the Universal Enrollment and Prescription Form



SYNAGIS[®] and SYNAGIS CONNECT[®] are registered trademarks of Arexis AB c/o Swedish Orphan Biovitrum AB (publ). © 2021 Swedish Orphan Biovitrum. All rights reserved. PP-10897 04/21